Related Experiment Video

Updated: Apr 28, 2026

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules
05:30

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules

Published on: August 16, 2011

19.8K

Treatment of intestinal cryptosporidiosis with spiramycin

D Portnoy, M E Whiteside, E Buckley

    Annals of Internal Medicine
    |August 1, 1984
    PubMed

    Insights

    Spiramycin effectively treated severe diarrhea caused by Cryptosporidium in immunocompromised patients. Most patients experienced complete symptom resolution, highlighting its therapeutic potential.

    Area of Science:

    • Infectious Diseases
    • Gastroenterology
    • Immunology

    Background:

    • Severe debilitating diarrhea is a common complication in immunocompromised individuals, including those with acquired immunodeficiency syndrome (AIDS) and recipients of allogeneic bone marrow transplants.
    • Cryptosporidium species are recognized opportunistic pathogens that can cause severe gastrointestinal distress in vulnerable patient populations.

    Purpose of the Study:

    • To evaluate the efficacy of spiramycin in treating severe diarrhea caused by Cryptosporidium in patients with acquired immunodeficiency syndrome (AIDS) and those who underwent allogeneic bone marrow transplantation.
    • To assess the clinical outcomes and resolution rates of Cryptosporidium-induced diarrhea following spiramycin treatment.

    Main Methods:

    • A cohort of ten patients (nine male with AIDS, one female with a history of allogeneic bone marrow transplant for acute myeloblastic leukemia) presenting with severe diarrhea was studied.
    • Stool samples were analyzed to confirm the presence of Cryptosporidium species.
    • Patients were treated with spiramycin for a duration of one week, with follow-up assessments to monitor symptom resolution and clinical improvement.

    Main Results:

    • Cryptosporidium species were identified in the stool samples of all ten patients.
    • Following one week of spiramycin treatment, five patients achieved complete resolution of their diarrhea.
    • Four additional patients experienced symptomatic improvement, and one patient showed a gradual response, with complete diarrhea resolution after 30 days of treatment.

    Conclusions:

    • Spiramycin demonstrates significant efficacy in managing severe diarrhea attributed to Cryptosporidium infections in immunocompromised patients.
    • The study suggests spiramycin as a viable therapeutic option for Cryptosporidium-related gastrointestinal complications in individuals with AIDS and post-bone marrow transplant patients.
    • Prompt treatment with spiramycin can lead to substantial clinical improvement and resolution of debilitating diarrhea in this vulnerable patient group.

    More Related Videos

    Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians06:49

    Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

    Published on: March 15, 2014

    11.3K
    Studying Cryptosporidium Infection in 3D Tissue-derived Human Organoid Culture Systems by Microinjection05:31

    Studying Cryptosporidium Infection in 3D Tissue-derived Human Organoid Culture Systems by Microinjection

    Published on: September 14, 2019

    9.2K

    Related Concept Videos

    Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

    Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

    Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
    593
    Drugs for Treatment of Diarrhea-Predominant IBS01:17

    Drugs for Treatment of Diarrhea-Predominant IBS

    Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
    Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
    1.0K
    Drugs for Treatment of Ulcerative Colitis in IBD01:29

    Drugs for Treatment of Ulcerative Colitis in IBD

    Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
    700
    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

    Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
    749
    Fungal Phylum Microsporidia01:28

    Fungal Phylum Microsporidia

    Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
    780
    Anthelminthic Agents01:15

    Anthelminthic Agents

    Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
    102